
Work Here?
Tecsys provides cloud-based supply chain software that helps organizations manage complex, omni-channel operations. Its products cover the end-to-end supply chain—from demand planning to order fulfillment—delivered primarily as software-as-a-service (SaaS) with professional services and training. The platform increases efficiency and visibility by offering integrated workflows for front-line workers and back-office planners, serving sectors like healthcare, retail, and logistics providers. Unlike some competitors, Tecsys combines a long-standing track record (founded in 1983) with a broad product suite that emphasizes both planning and execution across diverse industries. The goal is to help customers navigate rapidly changing market conditions and improve operational performance across the entire supply chain.
Industries
Data & Analytics
Industrial & Manufacturing
Enterprise Software
Healthcare
Company Size
501-1,000
Company Stage
IPO
Headquarters
Montreal, Canada
Founded
1983
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Total Funding
$27M
Above
Industry Average
Funded Over
3 Rounds
Remote Work Options
Tecsys beats Q1 estimates, raises guidance, plus another big quantum move. Tecsys posted a profit surprise of roughly 91% versus what analysts expected, and the stock still needed a full day to catch up. In California, the federal government agreed to take an equity stake in a publicly traded quantum computing company as a condition of writing it a $100 million check, the kind of arrangement usually reserved for airlines and banks in a crisis, not R&D grants. Tecsys beats Q1 FY2027 estimates, raises full-year guidance. Tecsys Inc. (TSX: TCS) reported first-quarter fiscal 2027 revenue of $50.05 million and earnings of $0.21 per diluted share, beating analyst estimates of $47.71 million and $0.11 per share, for results released September 10 after market close. Net profit rose 306% year over year to $3.1 million, and Adjusted EBITDA surged 113% to $6.9 million, a 13.7% margin near the top of the company's full-year guidance range. CEO Peter Brereton called it one of the strongest quarters in its history, pointing to the second-highest bookings quarter Tecsys has ever recorded. SaaS and recurring revenue reached 60% of total revenue, up from 58% in fiscal 2026 and 50% in fiscal 2024, and the trailing-twelve-month SaaS net retention rate reached 111%. Tecsys raised its full-year guidance across total revenue, SaaS revenue growth, and Adjusted EBITDA margin following the results. Shares rose roughly 8.6% to $31 in the days following the release. Separately, on September 9, Tecsys announced that Prisma Health, a nonprofit health system serving 1.6 million patients across 19 hospitals in South Carolina, is expanding its use of Tecsys' Hospital Point of Use technology beyond the warehouse and pharmacy systems it already runs. Management noted that the current quarter's margin strength, near the top of full-year guidance, may not repeat at the same pace given planned continued investment. Rigetti signs $100 million CHIPS Act deal, gives US government equity stake. Rigetti Computing, Inc. (Nasdaq: RGTI) signed a definitive agreement with the U.S. Department of Commerce for $100 million in CHIPS Act funding to accelerate superconducting quantum computing research, with the funding split across three projects: miniaturized readout electronics, expanded cryogenic capacity through a new cryostat architecture, and advanced fabrication capabilities at Rigetti's Fab-1 facility. As a condition of the award, the Department of Commerce will receive a minority, non-controlling equity stake in Rigetti. CEO Dr. Subodh Kulkarni said AktieGo is proud to be selected by the U.S. government to accelerate R&D against the company's scaling roadmap. The same day, D-Wave Quantum and Quantinuum each finalized identical $100 million CHIPS Act agreements with the same minority equity-stake structure, bringing the total to $300 million across three quantum computing companies as part of a broader federal program allocating $2 billion across nine quantum companies, with IBM receiving the largest share at $1 billion for a quantum chip foundry in Albany, New York. Shares of all three companies rose in premarket trading, with Rigetti up 7.4% to $16.33. The equity stake dilutes existing Rigetti shareholders even though it is non-controlling, and Rigetti shares remain down more than 31% year to date heading into this announcement. TCS, RGTI: Forward-Looking FAQ. Does Tecsys' raised full-year guidance already assume its Q1 margin strength continues at the same pace? Not necessarily. Management specifically flagged that the 13.7% Adjusted EBITDA margin, near the top of full-year guidance, reflects a strong quarter that may not repeat at the same rate given planned continued investment. Does the U.S. government's equity stake give it control over Rigetti's operations? No. The stake is explicitly structured as minority and non-controlling, so Rigetti's existing management and board retain operating control, though the stake does dilute existing shareholders and ties the company to R&D milestone and compliance obligations under the agreement. Sources. Editorial disclosure. This roundup is based entirely on publicly available information including named wire service releases and financial news reporting. Securities discussed include Tecsys Inc. (TSX: TCS) and Rigetti Computing, Inc. (Nasdaq: RGTI). aktiego.com has not received any compensation from any company, IR firm, or third party mentioned. No staff member or principal of aktiego.com holds a position in any security mentioned at the time of publication. Tecsys' press release date is confirmed as September 10, 2026; management has flagged that the quarter's margin strength may not repeat at the same pace. Rigetti's press release is dated September 8, 2026, one day outside the rolling 7-day window, included given the significance of a federal government equity stake in a publicly traded company; the stake dilutes existing shareholders and Rigetti shares remain down more than 31% year to date. Small cap and micro-cap stocks listed on the CSE, TSX, TSXV, and Nasdaq are speculative investments carrying significant risk including potential total loss of capital. Coverage on aktiego.com is provided for informational and educational purposes only. aktiego.com is not a registered investment advisor. Nothing in this article constitutes financial, investment, or professional advice. Readers are encouraged to conduct their own due diligence and consult a qualified financial advisor before making any investment decisions. For more information please see its full DISCLAIMER More market insights on youtube. Watch its latest market briefings, CEO interviews and stock deep dives covering the companies and sectors AktieGo follow. Market Briefings 3x per week Stock Deep Dives In-depth analysis CEO Interviews Exclusive insights Emerging Sectors Mining · Tech · Energy · Biotech The AktieGo Brief The market moves fast. Its briefing keeps up. Curated updates on stock picks, company spotlights, and in-depth market analysis across mining, biotech, energy, crypto, and tech - delivered straight to your inbox. Join thousands of investors who start their morning with the AktieGo Brief. By submitting your information, you're giving AktieGo permission to email you. No spam, no excessive emails. You may unsubscribe at any time.
Tecsys Q1 earnings call highlights. Tecsys (TSE:TCS) opened fiscal 2027 with record first-quarter revenue, record adjusted EBITDA and what Chief Executive Officer Peter Brereton described as the company's second-highest bookings quarter ever, led primarily by expansions among existing healthcare customers. For the quarter ended July 31, 2026, total revenue rose 9% year over year to C$50 million, or 8% on a constant-currency basis. Net profit increased 306% to C$3.1 million, or C$0.21 per diluted share, from C$0.8 million a year earlier. Adjusted EBITDA more than doubled to C$6.9 million from C$3.2 million. "Q1 delivered record bookings, in fact, the second highest bookings quarter Tecsys has ever recorded," Brereton said. "The story this quarter was expansion." Healthcare expansions lead bookings. Brereton said existing users of Tecsys' Elite platform, particularly healthcare organizations, expanded their deployments during the quarter. He cited Prisma Health, UT Southwestern Medical Center and a leading cancer treatment center as health systems that increased their relationships with the company. At Prisma Health, South Carolina's largest private nonprofit health system, Tecsys' expansion moved beyond earlier warehouse and pharmacy inventory deployments to include hospital point-of-use technology across its network. Brereton said the deployment is intended to provide greater visibility for clinical and supply-chain teams supporting 1.6 million patients annually across 19 hospitals. While healthcare was the principal source of expansion activity, Tecsys also reported SaaS migrations among general-distribution customers, including Rinchem, as well as a new European life-sciences customer. During the question-and-answer session, Brereton said first-quarter bookings were "heavily slanted towards expansions." New-account bookings were light, which he characterized as typical for the company's summer quarter, while bookings from migrations of legacy on-premise customers have diminished as more of that customer base has already moved to SaaS. He said more than 90% of pipeline activity is now split relatively evenly between new-account opportunities and expansions among existing SaaS customers, with migrations representing a smaller component. SaaS growth and contract backlog accelerate. Total SaaS revenue rose 18% to C$22.7 million from C$19.1 million in the prior-year quarter, or 17% in constant currency. Elite SaaS revenue, the company's core product offering, grew 24%, or 23% on a constant-currency basis. Total SaaS annual recurring revenue reached C$93.7 million at quarter-end, up 18% year over year. Tecsys separately disclosed Elite SaaS ARR of C$89.6 million, up 24% from a year earlier, or 22% in constant currency. Remaining performance obligations, a measure of contracted future revenue, reached C$259.2 million, surpassing C$250 million for the first time. The figure was up 14% year over year, or 13% in constant currency. Brereton said the expansion activity reflected customers' increasing use of TecsysIQ, the company's data and AI capabilities. He said customers need broader deployment of Tecsys' underlying platform to provide data for the AI engine, and that Tecsys is not seeing customers purchase its latest platform without TecsysIQ. The company is developing additional AI features, including expanded labor-management capabilities within its warehouse management system. Brereton also said Tecsys continued advancing its FedRAMP certification process and expects full certification by late winter or early spring, assuming the audit process proceeds as anticipated. Guidance raised after earlier-than-expected bookings. Chief Financial Officer Mark Bentler said Tecsys raised its fiscal 2027 outlook based on strong Elite SaaS bookings, pipeline strength and robust hardware bookings. The company now expects: * Elite SaaS revenue growth of 21% to 23%, up from prior guidance of 18% to 20%. * Total SaaS revenue growth of 16% to 18%, up from 13% to 15%. * Total revenue growth of 5% to 8%, up from 2% to 4%. * Adjusted EBITDA margin of 11% to 14%, compared with prior guidance of 11% to 13%. Bentler said a portion of SaaS bookings that management had expected later in the fiscal year closed earlier than anticipated, increasing the amount of revenue that can be recognized during the year. He also pointed to substantial hardware bookings late in the first quarter and early in the second quarter, for which the company has visibility into delivery timing. Despite the strong first-quarter adjusted EBITDA margin of 13.7%, near the upper end of the revised guidance range, Bentler said Tecsys expects to increase investment through hiring across several functional areas during the remainder of the fiscal year. Professional-services bookings were lighter during the quarter, reducing the related backlog. Bentler said professional-services revenue is expected to decline slightly sequentially in the second quarter, though he noted such demand often follows SaaS bookings with a timing lag as customers proceed with deployment planning. Brereton said several statements of work and project charters were being finalized and could replenish that backlog in the near term. Tecsys ended the quarter with C$35 million in cash and short-term investments and no debt. The company repurchased 17,400 shares for about C$0.6 million under its normal course issuer bid, and its board approved a quarterly dividend of C$0.09 per share. Track Stocks Bonds About Tecsys (TSE:TCS). Tecsys is trusted by mission-critical organizations in healthcare and distribution to build resilient, efficient and secure supply chains. A global provider of cloud-based, AI-driven software with deep domain expertise, Tecsys delivers real-time operational visibility and execution across critical workflows when performance and reliability matter most. Tecsys is publicly traded on the Toronto Stock Exchange (TCS). For more information, visit www.tecsys.com.
Prisma Health extends Tecsys partnership from distribution center to bedside. Sep 09, 2026, 08:00 ET South Carolina's largest private, nonprofit health system adds Tecsys' Hospital Point of Use to its supply chain stack MONTREAL, Sept. 9, 2026 /CNW/ - Tecsys Inc. (TSX: TCS), an industry-leading supply chain management company, today announced that Prisma Health, the largest private, nonprofit health company in South Carolina, is deploying Tecsys' Hospital Point of Use (POU) technology across its hospitals to improve visibility into product use at the point of care. The rollout of POU extends a Tecsys supply chain technology stack at Prisma Health that already includes Warehouse Management System (WMS) and Pharmacy Inventory Management System (PIMS), which is going live later this year. Prisma Health supports 1.6 million patients every year across its 19 acute care and specialty hospitals. Tecsys solutions will also support Prisma Health's new 112-bed behavioral health hospital under construction near Easley, South Carolina, scheduled to open in 2027. Delivering care at that scale depends on knowing exactly what is on hand, where it is and when it needs to be replaced, across all care settings. Prisma Health first went live on the Tecsys platform in August 2020 with WMS in its distribution center, a foundation the health system is now building upon as PIMS and POU roll out. Tecsys' POU captures product consumption at the bedside and in procedural areas, in real time, supporting more accurate charge capture, faster recall response, less waste and more accurate replenishment demand, all without adding a single step for the people delivering care and ensuring confidence in every case. "Health systems need to know more than what they purchased and when. They need to know what is available, where it is and whether it will be there when care teams need it," said Peter Brereton, CEO of Tecsys. "A missing medication or supply shouldn't be the reason care is delayed. Prisma Health is extending that visibility from the distribution center to the point of care, helping its teams identify and address supply issues before they can affect the patient." Together, Tecsys' WMS, PIMS and POU solutions give Prisma Health a connected view of inventory from the receiving dock to the bedside, delivering enterprise-wide visibility and control for managing medical supplies and medications across a growing health system. About Prisma Health Recognized as one of "America's Most Innovative Companies" by Fortune, Prisma Health is a private nonprofit health company with over 32,000 team members, 19 acute and specialty hospitals, 3,131 licensed beds, 320 practice sites, and more than 5,900 employed and independent clinicians across its clinically integrated inVio Health Network. Each year, Prisma Health serves more than 1.6 million patients in South Carolina and Tennessee. Connect with Prisma Health on Facebook, Instagram, LinkedIn, Twitter/X and TikTok. Visit PrismaHealth.org. About Tecsys Tecsys is trusted by mission-critical organizations in healthcare and distribution to build resilient, efficient and secure supply chains. A global provider of cloud-based, AI-driven software with deep domain expertise, Tecsys delivers real-time operational visibility and execution across critical workflows when performance and reliability matter most. Tecsys is publicly traded on the Toronto Stock Exchange (TSX: TCS). For more information, visit www.tecsys.com. SOURCE Tecsys Inc. Public Relations: Belinda Thomas [email protected]; General Information: [email protected]; Investor Relations: [email protected]; By Phone: (514) 866-0001 or (800) 922-8649
Tecsys earns Great Place To Work(R) Certification in Canada, the U.S., Denmark and India for the third consecutive year. Posted by: Tecsys July 15, 2026 91% of employees say Tecsys is a great place to work; company Trust Index rises to 86% Montreal, July 15, 2026 - Tecsys Inc. (TSX: TCS), an industry-leading supply chain management company, today announced it has earned Great Place To Work(R) Certification(TM) in Canada, the United States, Denmark and India, marking the third consecutive year the company has achieved this recognition in every country where it operates. Great Place To Work Certification is based entirely on what employees say about their experience, gathered through the organization's Trust Index survey and benchmarked against thousands of companies worldwide. This year, 91% of Tecsys employees said that Tecsys is a great place to work, and the company's overall Trust Index score rose to 86%, up four points from 2024. "Being certified for a third consecutive year in every country where we operate is something we are incredibly proud of," said Nancy Cloutier, Chief Human Resources Officer at Tecsys. "While every location has its own culture and unique perspective, our employees consistently tell us they experience the same foundation of trust, support and pride. That consistency reflects our commitment to creating a workplace where people can do their best work and truly belong." Employees cited fairness, feeling welcome, flexibility and a positive working environment among the survey's strongest results, alongside the way colleagues support one another. "Culture shows up in how we serve customers and in the consistency, care and expertise our teams bring every day," said Peter Brereton, President and CEO of Tecsys. "Being recognized for a third year in every market we serve reflects the kind of company we're building for the long term." Great Place To Work(R) is the global authority on workplace culture. Each year, it surveys more than 100 million employees worldwide and uses that data to help companies quantify and improve their culture. About Tecsys Tecsys is trusted by mission-critical organizations in healthcare and distribution to build resilient, efficient and secure supply chains. A global provider of cloud-based, AI-driven software with deep domain expertise, Tecsys delivers real-time operational visibility and execution across critical workflows when performance and reliability matter most. Tecsys is publicly traded on the Toronto Stock Exchange (TSX: TCS). For more information, visit www.tecsys.com. Media contacts Sean Chase Account Director, Greenough Communications for Tecsys [email protected] +1 617 275 6531 Belinda Thomas VP, Communications & Brand [email protected] +1 613 322 9305
Tecsys, a supply chain management software company, reported record revenue of $50 million in its fourth quarter of fiscal 2026, up from $46.6 million in the prior year. Elite SaaS revenue grew 21%, whilst adjusted EBITDA rose 56% to $6.7 million. For the full fiscal year ended 30 April 2026, total revenue reached a record $193.1 million, up from $176.5 million. Total SaaS revenue increased 20% to $80.4 million. Adjusted EBITDA for the year was $20 million, representing a 10% margin and exceeding guidance of 8-9%. The company posted a net loss of $0.2 million in Q4 due to $4.7 million in restructuring costs. SaaS annual recurring revenue increased 13% to $86.8 million. Tecsys declared a quarterly dividend of $0.09 per share.
Find jobs on Simplify and start your career today
Industries
Data & Analytics
Industrial & Manufacturing
Enterprise Software
Healthcare
Company Size
501-1,000
Company Stage
IPO
Headquarters
Montreal, Canada
Founded
1983
Find jobs on Simplify and start your career today